Effectiveness and Safety of Long-Term Dupilumab Treatment in Elderly Patients with Atopic Dermatitis: A Multicenter Real-Life Observational Study.
Age Factors
Aged
Aged, 80 and over
Antibodies, Monoclonal, Humanized
/ administration & dosage
Conjunctivitis
/ chemically induced
Dermatitis, Atopic
/ complications
Drug Administration Schedule
Female
Humans
Injection Site Reaction
/ epidemiology
Injections, Subcutaneous
Male
Pruritus
/ diagnosis
Quality of Life
Retrospective Studies
Severity of Illness Index
Time Factors
Treatment Outcome
Journal
American journal of clinical dermatology
ISSN: 1179-1888
Titre abrégé: Am J Clin Dermatol
Pays: New Zealand
ID NLM: 100895290
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
pubmed:
17
3
2021
medline:
14
9
2021
entrez:
16
3
2021
Statut:
ppublish
Résumé
The objective of this study was to assess the effectiveness and safety of dupilumab in treating elderly patients with atopic dermatitis from baseline to 52 weeks. A retrospective observational real-life study was conducted in a group of elderly patients with severe atopic dermatitis treated with dupilumab for 52 weeks. Inclusion criteria were: age ≥ 65 years; diagnosis of atopic dermatitis made by an expert dermatologist; Eczema Area and Severity Index ≥ 24; and a contraindication, side effects, or failure to respond to cyclosporine. The primary outcome was the mean percentage reduction in the Eczema Area and Severity Index score from baseline to week 52. Secondary measures included the mean percentage reduction in the Pruritus and Sleep Numerical Rating Scales and the Dermatology Life Quality Index, and the types and rates of adverse events from baseline to week 52. One hundred and five patients were eligible for the study. Flexural dermatitis was the most frequent clinical phenotype (63.8%). The coexistence of more than one clinical phenotype was found in 70/105 (66.6%) patients. We observed a reduction in all disease severity scores from baseline to week 52 (p < 0.001). Adverse events were recorded in 30/105 (28.6%) patients, with conjunctivitis and injection-site reaction the most frequent. In this study, dupilumab is an effective and safe treatment for the long-term management of atopic dermatitis in patients aged over 65 years.
Identifiants
pubmed: 33725337
doi: 10.1007/s40257-021-00597-5
pii: 10.1007/s40257-021-00597-5
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
dupilumab
420K487FSG
Types de publication
Journal Article
Multicenter Study
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
581-586Investigateurs
L Angileri
(L)
T Bianchelli
(T)
A Borghi
(A)
G Calabrese
(G)
C Chello
(C)
G Dal Bello
(G)
S Dastoli
(S)
M Ferrillo
(M)
M Galluzzo
(M)
N Gori
(N)
K Hansel
(K)
L Macchia
(L)
V Piras
(V)
E Provenzano
(E)
S Ribero
(S)
M Romanelli
(M)
P Romita
(P)
Références
Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389:2287–303.
doi: 10.1016/S0140-6736(17)31191-1
Worm M, Simpson EL, Thaçi D, et al. Efficacy and safety of multiple dupilumab dose regimens after initial successful treatment in patients with atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156:131–43.
doi: 10.1001/jamadermatol.2019.3617
Armario-Hita JC, Pereyra-Rodriguez J, Silvestre JF, et al. Treatment of moderate-to-severe atopic dermatitis with dupilumab in real clinical practice: a multicentre, retrospective case series. Br J Dermatol. 2019;181:1072–4.
doi: 10.1111/bjd.18041
Ruiz-Villaverde R, Dominguez-Cruz J, Armario-Hita JC, Martinez-Pilar L, Alcantara-Luna S, Pereyra- Rodriguez JJ. Fifty-two week follow-up safety and effectiveness results of dupilumab treatment of moderate-to-severe atopic dermatitis from a retrospective, multicentric series. Dermatol Ther. 2019;32:e12931.
doi: 10.1111/dth.12931
Jo CE, Georgakopoulos JR, Ladda M, et al. Evaluation of long-term efficacy, safety, and reasons for discontinuation of dupilumab for moderate to severe atopic dermatitis in clinical practice: a retrospective cohort study. J Am Acad Dermatol. 2020;82:1530–2.
doi: 10.1016/j.jaad.2020.02.029
Fargnoli MC, Esposito M, Ferrucci S, Dupilumab Italian National Access Program (Dup-INAP Group), et al. Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis. J Dermatolog Treat. 2019;28:1–7.
doi: 10.1080/09546634.2019.1682503
Fargnoli MC, Esposito M, Ferrucci S, et al. A 48-week update of a multicentre real-life experience of dupilumab in adult patients with moderate-to-severe atopic dermatitis. J Dermatolog Treat. 2020;3:1–4.
doi: 10.1080/09546634.2020.1773379
Nettis E, Fabbrocini G, Ortoncelli M, et al. Long-term effectiveness of dupilumab up to 52 weeks in atopic dermatitis in 253 adult patients. Br J Dermatol. 2020 (epub ahead of print).
Napolitano M, Fabbrocini G, Scalvenzi M, Blasio C, Stingeni L, Patruno C. Efficacy and safety of dupilumab in atopic dermatitis in elderly patients: a retrospective study. Clin Exp Dermatol. 2020;45:888–90.
doi: 10.1111/ced.14260
Patruno C, Napolitano M, Argenziano G, Peris K, Ortoncelli M, Girolomoni G, et al. Dupilumab therapy of atopic dermatitis of the elderly: a multi-centre, real-life study. J Eur Acad Dermatol Venereol. 2020 (epub ahead of print).